| 4.3 0.41 (10.54%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.13  |
1-year : | 7.16 |
| Resists | First : | 5.25 |
Second : | 6.13 |
| Pivot price | 4.32 |
|||
| Supports | First : | 3.79 |
Second : | 2.9 |
| MAs | MA(5) : | 4.17 |
MA(20) : | 4.18 |
| MA(100) : | 2.69 |
MA(250) : | 2.73 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 43.6 |
D(3) : | 43.8 |
| RSI | RSI(14): 56.1 |
|||
| 52-week | High : | 5.25 | Low : | 1.62 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ HSCS ] has closed above bottom band by 48.9%. Bollinger Bands are 85.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 29 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.41 - 4.44 | 4.44 - 4.47 |
| Low: | 3.86 - 3.89 | 3.89 - 3.91 |
| Close: | 4.26 - 4.31 | 4.31 - 4.35 |
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
Fri, 02 Oct 2026
HeartSciences Extends $500,000 FRV Secured Loan to Earlier of Post-Merger Close or Jan. 29, 2027 - TradingView
Wed, 30 Sep 2026
HeartSciences Submits Supplemental Proxy Materials Detailing Fortitude Merger and New Legal Appointment - Kalkine Media
Fri, 18 Sep 2026
HeartSciences to Merge with Fortitude Mining, Rebrand - The Globe and Mail
Mon, 14 Sep 2026
HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Wed, 19 Aug 2026
HeartSciences Announces $1 Million Fortitude Investment at 22% Premium Ahead of Proposed Merger - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | -3 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 4.51e+006 (%) |
| Held by Institutions | 2.72e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 2550 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.49 |
| Profit Margin | 0 % |
| Operating Margin | -194 % |
| Return on Assets (ttm) | 787.3 % |
| Return on Equity (ttm) | -110.9 % |
| Qtrly Rev. Growth | 239.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -213.59 |
| EBITDA (p.s.) | 2804.46 |
| Qtrly Earnings Growth | -8.39e+006 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -1.24 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0 |
| Dividend | 50680 |
| Forward Dividend | 77600 |
| Dividend Yield | 1178600% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|